Young Suk Park
Papers
1
Total Citations
25
H-Index
1
About
Young Suk Park is a leading figure in gastrointestinal oncology, with a primary focus on optimizing multimodal treatment strategies for rectal cancer. His research centers on chemoradiotherapy sequencing, surgical timing, and the refinement of neoadjuvant protocols to improve patient outcomes. Park’s most cited work, the phase II multi-institutional KROG 11-02 trial (2014), demonstrated the feasibility and safety of a two-week course of preoperative chemoradiotherapy followed by delayed surgery, offering a condensed alternative to conventional long-course regimens. This study, with 25 citations, has informed clinical decision-making by balancing treatment intensity with surgical recovery. Beyond this landmark trial, Park has contributed to the broader understanding of radiotherapy dose fractionation and pathological response assessment, helping to shape evidence-based guidelines in colorectal cancer management. His collaborative efforts through the Korean Radiation Oncology Group (KROG) underscore his commitment to multi-center research that directly translates to clinical practice. For students and researchers, Park’s work exemplifies how rigorous trial design can address practical challenges in cancer care, bridging the gap between radiation oncology and surgical oncology.
Research Focus
Key Achievements
Top Papers
- 1